NasdaqCM:MBRX

Stock Analysis Report

Executive Summary

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Moleculin Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MBRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.3%

MBRX

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

-45.0%

MBRX

12.6%

US Biotechs

17.8%

US Market

Return vs Industry: MBRX underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: MBRX underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

MBRXIndustryMarket
7 Day1.3%0.7%-1.1%
30 Day-18.1%5.9%1.5%
90 Day-25.2%6.1%6.6%
1 Year-45.0%-45.0%13.5%12.6%20.2%17.8%
3 Year-35.8%-35.8%21.9%18.7%47.5%38.1%
5 Yearn/a2.9%-1.8%71.2%52.4%

Price Volatility Vs. Market

How volatile is Moleculin Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Moleculin Biotech undervalued compared to its fair value and its price relative to the market?

1.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MBRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MBRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MBRX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MBRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MBRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MBRX is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Moleculin Biotech forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

45.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MBRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MBRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MBRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MBRX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if MBRX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MBRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Moleculin Biotech performed over the past 5 years?

-35.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MBRX is currently unprofitable.

Growing Profit Margin: MBRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MBRX is unprofitable, and losses have increased over the past 5 years at a rate of -35.4% per year.

Accelerating Growth: Unable to compare MBRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MBRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: MBRX has a negative Return on Equity (-64.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Moleculin Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: MBRX's short term assets ($18.6M) exceed its short term liabilities ($11.1M).

Long Term Liabilities: MBRX's short term assets ($18.6M) exceed its long term liabilities ($304.0K).


Debt to Equity History and Analysis

Debt Level: MBRX is debt free.

Reducing Debt: MBRX had no debt 5 years ago.


Balance Sheet

Inventory Level: MBRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if MBRX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MBRX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MBRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -47.6% each year


Next Steps

Dividend

What is Moleculin Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MBRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MBRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MBRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MBRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MBRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Wally Klemp (59yo)

4.6yrs

Tenure

US$1,345,675

Compensation

Mr. Walter V. Klemp, also known as Wally, founded Moleculin Biotech, Inc. in July 2015 and has been its Chief Executive Officer since July 2015 and President since August 23, 2017. He has been Director at  ...


CEO Compensation Analysis

Compensation vs Market: Wally's total compensation ($USD1.35M) is above average for companies of similar size in the US market ($USD522.48K).

Compensation vs Earnings: Wally's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Walter Klemp
Founder4.6yrsUS$1.35m2.12% $745.1k
Jonathan Foster
Executive VP & CFO3.5yrsUS$845.69k0.022% $7.7k
Donald Picker
Chief Scientific Officer2.5yrsUS$439.41k1.02% $360.8k
Waldemar Priebe
Co-Founder and Chairman of Scientific Advisory Board0yrsno data6.08% $2.1m
Robert Shepard
Chief Medical Officer3.7yrsno datano data
Sandra Silberman
Chief Medical Officer of New Products2.3yrsno datano data
Jacqueline Northcut
Consultant2.6yrsUS$69.23kno data
Louis Ploth
Independent Advisor3.5yrsUS$118.49kno data

3.5yrs

Average Tenure

63yo

Average Age

Experienced Management: MBRX's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Walter Klemp
Founder4.6yrsUS$1.35m2.12% $745.1k
Waldemar Priebe
Co-Founder and Chairman of Scientific Advisory Board0yrsno data6.08% $2.1m
Michael Cannon
Independent Director3.7yrsUS$100.70kno data
Jorge Cortes
Member of Scientific Advisory Board2.1yrsno datano data
John Waymack
Member of Scientific Advisory Board0yrsno datano data
John Climaco
Lead Independent Director2.6yrsUS$110.70kno data
Elihu Estey
Member of Scientific Advisory Board2.1yrsno datano data
Martin Tallman
Member of Scientific Advisory Board0.9yrsno datano data
Robert George
Independent Director3.7yrsUS$106.95k0.0022% $771.1
James Abbruzzese
Member of Science Advisory Board1.1yrsno datano data

2.3yrs

Average Tenure

67yo

Average Age

Experienced Board: MBRX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.5%.


Top Shareholders

Company Information

Moleculin Biotech, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moleculin Biotech, Inc.
  • Ticker: MBRX
  • Exchange: NasdaqCM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$35.210m
  • Shares outstanding: 45.73m
  • Website: https://www.moleculin.com

Number of Employees


Location

  • Moleculin Biotech, Inc.
  • 5300 Memorial Drive
  • Suite 950
  • Houston
  • Texas
  • 77007
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MBRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2016
MOLDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2016
0K2HLSE (London Stock Exchange)YesCommon StockGBUSDJun 2016

Biography

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and lung-localized tumors. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122, a prodrug of 2-deoxyglucose to treat brain tumors and pancreatic cancer. In addition, it develops WP1234 for the treatment of pancreatic cancer. Further, the company engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. It has an agreement with the University of Iowa Pharmaceuticals for the development of a formulation for WP1732; collaboration with Dermin Sp. Zoo for the development of WP1220; and collaboration with M.D. Anderson Cancer Center for the development of WP1732 and WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 00:51
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.